Press releases

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets


Check out our website and subscribe to our newsletter (at the bottom) to hear the latest as we grow.… http://bcPCRw0EBS

To achieve this, we will disrupt immunosuppressive pathways to empower a broader, durable immune response to tumors… http://tPXTbQzwS1

At Kyn, we envision a future where immunotherapies are the foundation of every #cancer patient's treatment. http://UFMERiDGKh

AHR is an immunosuppressive receptor we're exploring as a target in our preclinical activity - read more about it:… http://ChoiK5WXTY

Media contact

Tom Donovan
Ten Bridge Communications


Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us


Email us

Friend us